{"disease":{"id":"acute-leukemia-relapsed","name":"acute leukemia relapsed"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06581081","title":"Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05061147","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Maxinovel Pty., Ltd.","has_results":false},{"nct_id":"NCT05334823","title":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04424147","title":"Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT02228096","title":"Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07366801","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04797767","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT06869265","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05805605","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04541277","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03560882","title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Joaquina Baranda","has_results":false},{"nct_id":"NCT06906380","title":"A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":49,"lead_sponsor_name":"ARCE Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06783816","title":"A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Shanxi Bethune Hospital","has_results":false},{"nct_id":"NCT05951855","title":"Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT03985007","title":"CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03516760","title":"Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"AvenCell Europe GmbH","has_results":false},{"nct_id":"NCT04191187","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04139434","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT05190549","title":"CAV Regimen Bridging to HSCT for R/R AL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04204161","title":"A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Shenzhen BinDeBio Ltd.","has_results":false},{"nct_id":"NCT02957032","title":"A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Philogen S.p.A.","has_results":false},{"nct_id":"NCT05787496","title":"A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT04092179","title":"Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05028751","title":"A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Kronos Bio","has_results":true},{"nct_id":"NCT03156101","title":"A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Shenzhen BinDeBio Ltd.","has_results":false},{"nct_id":"NCT06397027","title":"A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03674411","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05495035","title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":22,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06466395","title":"A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05029141","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03265106","title":"A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shenzhen BinDeBio Ltd.","has_results":false},{"nct_id":"NCT05679687","title":"ThisCART19A Bridging to alloHSCT for R/R B-ALL","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06054113","title":"Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02109627","title":"Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"C. Babis Andreadis","has_results":false},{"nct_id":"NCT03063203","title":"Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT06017258","title":"A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05105867","title":"CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT03393611","title":"CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT03187288","title":"Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05038800","title":"A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04668885","title":"CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02808442","title":"Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}